Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

By H. Scher, C. Sawyers. Journal of Clinical Oncology, 2005

1,042 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d7274dc36019fdbf947782e80dcc29fb7a83384e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. John Wongvipat
2. C. Sawyers
3. Andrew J. Vickers

In Genetics

1. C. Sawyers
2. John Wongvipat
3. Andrew J. Vickers
4. Misop Han
5. Zhaohui S. Qin
6. Alan W. Partin
7. Arul M. Chinnaiyan
8. Nicholas D. Socci

In Pulmonary and Respiratory Medicine

1. Arul M. Chinnaiyan
2. John Wongvipat
3. C. Sawyers
4. Philip A Watson
5. R. Vessella
6. Andrew J. Vickers
7. Hans Lilja
8. Ewout W. Steyerberg

Citations in the corpus

• Prostate-specific antigen and prostate cancer: prediction, detection and monitoring (2008, background): “Androgen receptor reactivation, which may be caused by mutation, gene duplication or other mechanisms, is a common feature of androgen-independent prostate cance”
• ARN-509: a novel anti-androgen for prostate cancer treatment (2012, positive): “This cell-line was engineered to over-express AR (3–5 fold higher than parental LNCaP), thus mimicking the castration-resistant clinical state (2, 13).”
• Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. (2008, background): “Many reports address the former with a variety of suspect proteins and signaling pathways implicated (2, 22).”
• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer (2008, background): “Median OS of Favorable and Unfavorable CTC and 30% and 50% PSA decrement groups in CRPC patients Time Point CTC/7.5 mL 30% PSA Reduction from baseline (”
• Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011, neutral): “Dyspnea 102 (13) 8 (1) 2 (<1) 46 (12) 7 (2) 2 (<1)”
• Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor (2010, positive): “AR signaling is required for development of the normal prostate (3) and prostate cancer progression, even in the end stage of castration-resistant disease (4).”
• An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression (2010, background): “Tumors from men with castration-resistant metastatic prostate cancer (CRMPC) often overexpress AR through multiple mechanisms including AR amplification (Scher and Sawyers, 2005).”
• Increased survival with enzalutamide in prostate cancer after chemotherapy. (2012, neutral): “Adverse event leading to death 23 (3) 23 (3) 14 (4) 14 (4)”
• LncRNA-Dependent Mechanisms of Androgen Receptor-regulated Gene Activation Programs (2013, background): “0001; (3) fold enrichment over local tag count, default: 4.”
• Ligand-independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone Refractory Prostate Cancer (2009, positive): “Molecular alterations involving AR itself, such as AR overexpression and gain-of-function AR LBD mutations, are common in HRPC and allow for continued AR-mediated genomic functions under the presence of reduced or altered ligands (5, 6).”